In brief
Allan Shaw, a life sciences CFO, argues that biopharma success rests on disciplined capital allocation and strong people. In his view, the goal is bringing an impactful drug to patients. Getting there takes steady, incremental steps. Those steps include spending as if money is scarce, hiring experienced operators, and running early experiments that can kill weak programs quickly.
The central tension is that capital is abundant now, which hides bad decisions and tempts companies to copy peers and chase trends. Shaw warns that the market will eventually tighten and fund only those who executed well with the money they had. He and host Matt Pillar also discuss how to reconcile fail-fast thinking with outside pressure to avoid visible failure.
Questions
How does Allan Shaw define success in biopharma?
He defines it as bringing a novel, impactful drug to market that helps patients and changes, or creates, a standard of care. He compares it to climbing a huge mountain that requires getting many incremental steps right.
Why is a lot of available investor money a problem for biotech companies?
Shaw says abundant capital leads to less discipline in choosing projects and taking risks, and it masks bad decisions. Companies that copy peers' spending may be caught out when the funding dries up.
What does 'jockeys versus horses' mean in this episode?
Shaw uses 'jockeys' to mean the management team and 'horses' to mean the drug assets. He would choose a top team with an average asset over the reverse, because a great asset can be ruined by the wrong people.
What are 'killer experiments' and why does Shaw recommend them?
They are tests designed to answer the most important questions about a drug as early as possible, so a failing program can be dropped quickly. Shaw says this saves time and money and helps validate the mechanisms that do work.
How should biotech companies deal with the pressure not to look like they are failing?
Shaw says companies should not be single-threaded, meaning dependent on one program. If a program is killed, a pipeline with several assets and different ways to win lets the company move on, as Syndax did.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
The Business of Biotech podcast, produced in partnership with Cytiva, was marking its one-year anniversary at the time of this episode.
“we will be celebrating our one-year anniversary of the Business of Biotech podcast, which coincides with the one-year anniversary of our partner and its production, Cytiva.”
0:00:19 · Matt Pillar · Podcast anniversary
Allan Shaw says the biopharmaceutical industry had been heavily criticized by the media and the world going into the year before this episode.
“the biopharmaceutical industry was the favorite whipping boy of the media and of the world”
0:02:07 · Allan Shaw · Industry reputation
Allan Shaw says the industry went from discovery to available COVID-19 vaccines in less than a year.
“in less than a year, we've been able to go from discovery to actually having drugs available to vaccinate against COVID-19”
0:02:59 · Allan Shaw · COVID-19 vaccines
Allan Shaw says oncology companies shifted from chasing immuno-oncology (IO) to chasing precision oncology as the trend of the day.
“You saw that a couple of years back. Every oncology company wanted to suddenly be in IO. Now I think it's fashionable to be in precision oncology.”
0:13:05 · Allan Shaw · Oncology trends
Allan Shaw says that after COVID-19 showed remote work was possible, biotech companies can recruit talent beyond hubs such as Cambridge, San Diego, Carolina and Philadelphia.
“You're no longer stuck to the hubs of Cambridge or the hubs of San Diego or Carolina or Philadelphia, for that matter.”
0:16:14 · Allan Shaw · Remote hiring
Allan Shaw says there are anecdotal reports of very high employee turnover in the Boston-Cambridge biotech market, with people moving between nearby companies.
“certainly in the Boston, Cambridge, you know, there's a lot of anecdotal stories about people just the turnover, just being incredible people just crossing the street”
0:19:26 · Allan Shaw · Talent retention
Allan Shaw says wealth creation for employees is associated with equity rather than cash pay, which he says covers overhead.
“if you want to create wealth and ultimately move the needle, it's good. Wealth creation is associated with the equity.”
0:20:04 · Allan Shaw · Equity compensation
Allan Shaw says delaying development does not save money because overhead continues to be spent, raising the cost of reaching success.
“But in fact, you're still burning overhead. So it's actually, you've actually incrementally increased the cost of success at the end of the day.”
0:23:29 · Allan Shaw · Development delays
Matt Pillar says he recently interviewed Dietrich Stefan, CEO of New Base Therapeutics, on the podcast about fail-fast, fail-cheap thinking.
“I recently had a conversation on this podcast with Dietrich Stefan, who's the CEO at New Base Therapeutics.”
0:25:10 · Matt Pillar · Prior guest
Allan Shaw cites the amyloid plaque hypothesis in Alzheimer's disease as an example of people sticking to a hypothesis despite scientific evidence pointing elsewhere.
“not to beat up on Alzheimer's or the amyloid plaque hypothesis, but that's a classic example of people really sticking very doggedly at a hypothesis”
0:27:13 · Allan Shaw · Alzheimer's research
Allan Shaw says he helped take Syndax, a former company of his, public a couple of years before this episode.
“one of my former companies, Syndax, which I helped take public a couple of years ago”
0:28:38 · Allan Shaw · Syndax IPO
Syndax went public with entinostat, an HDAC inhibitor in phase three with promise in immuno-oncology, as its single lead molecule.
“we did that with an HDAC, a Tinnostat, which was in phase three and had a lot of promise and IO, but it was one molecule.”
0:28:38 · Allan Shaw · Syndax lead drug
Allan Shaw says Syndax's entinostat program was later discontinued, and within six months the company brought in an antibody showing promise.
“the Tennis Stat program is no longer in development for a number of different reasons. But to the team's credit, you know, we within six months, we brought in an antibody that's showing some promise.”
0:29:16 · Allan Shaw · Syndax pipeline
Allan Shaw says Syndax now has a menin inhibitor that forms the fundamental basis of the company's investment thesis.
“They have an incredibly exciting menin inhibitor now. And that's really the fundamental basis of the company's investment thesis.”
0:29:51 · Allan Shaw · Menin inhibitor
Matt Pillar says he ran track in high school and college and was a 400-meter intermediate hurdler.
“I was a runner in high school and college and I had a track coach in college.”
0:30:30 · Matt Pillar · Host background
Allan Shaw cites ordering phase three drug product materials while still in phase two as an example of costly premature spending.
“where you are in terms of ordering phase three drug product materials when you're still in phase two”
0:33:38 · Allan Shaw · Manufacturing timing
Allan Shaw says biotech valuations at the time could not be rationalized by most sell-side analysts, raising questions about market durability.
“valuations are not currently at a level that can be rationalized by most sell side analysts”
0:37:04 · Allan Shaw · Market valuations
Allan Shaw predicts capital markets will tighten and investors will raise the bar on which biotech companies they fund.
“there's going to be some tightening and that the bars, they're going to raise the bar in terms of who they fund and who they don't fund.”
0:40:05 · Allan Shaw · Capital tightening